Riskpilot← Back to searchSign inGet full accessMirMed AB
ABActiveOrg 5592784473Rudbecksgatan 11 LEngineering activities and related technical consultancy · NACE 7112Est. 20201 employees
Revenue 2025
SEK 1,9M
+13% vs 2024
EBITDA margin
13.4%
-7% vs 2024
Equity ratio
59.3%
Financial strength
Net profit 2025
SEK 219K
+10% vs 2024
| Revenue | SEK 1,9M | +13% |
| EBITDA | SEK 254K | -7% |
| Net profit | SEK 219K | +10% |
| Total assets | SEK 424K | -22% |
| Equity | SEK 251K | +8% |
| Employees | 1 | — |
Legal name
MirMed AB
Org number
5592784473
Legal form
Aktiebolag
NACE code
7112 · Engineering activities and related technical consultancy
Founded
23 oktober 2020
Share capital
SEK 30 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget ska bedriva teknisk konsultverksamhet inom industriteknik samt handel med värdepapper, äga och förvalta andelar i andra bolag. Handel med och äga fastigheter. Handel med och äga fast egendom samt ävensom idka annan därmed förenlig verksamhet.
Address
Rudbecksgatan 11 L
Email
m.westerberg78@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 671 | 2 009 | 611 | 1 674 | 1 897 |
| Staff expenses | — | −1 067 | −312 | −950 | −1 153 |
| EBITDA | 430 | 483 | 5 | 273 | 254 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 430 | 483 | 5 | 273 | 254 |
| Net financials | 100 | — | −10 | −19 | 18 |
| Profit before tax | 330 | 383 | 95 | 254 | 272 |
| Tax | −92 | −82 | −21 | −55 | −53 |
| Net profit | 238 | 301 | 74 | 199 | 219 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 547 | 769 | 538 | 543 | 424 |
| Equity | 268 | 339 | 113 | 232 | 251 |
| Long-term debt | 0 | — | 59 | 0 | — |
| Short-term debt | 280 | 330 | 366 | 310 | 173 |
| Total debt | 280 | 330 | 425 | 310 | 173 |
EBITDA margin
13.4%
This company
15.8%
Market median
-15% vs market
20212025
Equity ratio
59.3%
This company
38.2%
Market median
+55% vs market
20212025
Return on equity
87.1%
This company
18.4%
Market median
+373% vs market
20212025
Net profit margin
11.6%
This company
8.1%
Market median
+43% vs market
20212025
Asset turnover
4.47×
This company
1.12×
Market median
+299% vs market
20212025
Debt / equity
0.69×
This company
0.62×
Market median
+11% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-10-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
LM Chief Executive Officer | Chief Executive Officer | 2020 |
ÅM Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
| Chairman | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MirMed AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Magnus Westerberg | Chief Executive Officer | 0 companies |
| Åsa Maria Westerberg | Deputy Chief Executive Officer | 0 companies |
| John Rickard Morgan Nurlin | Chairman | 0 companies |